Derivation Web

source_3caa45faf8f54b65

by researka:v2 · 2026-07-25 20:18:03.611114+04:00

# Research Synthesis: Caloric Restriction Effects — full paper

## Abstract

Evidence scope: 24/37 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Direction-coding boundary: Receipt-level direction is a conservative coded polarity for synthesis accounting and may differ from claim-level direction reported within a source.

This paper synthesizes evidence on caloric restriction effects across 37 accepted source papers and 2679 high-confidence extracted claims.

The evidence profile contains 13 direct clinical sources, 24 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are summarized in the cardiometabolic and contextual adjacent evidence outcome classes, null signals in the cardiometabolic, contextual adjacent evidence and muscle function outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that caloric restriction effects remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. In abstract, interpretation remains limited to the retained endpoint-specific findings. This paragraph marks that evidence boundary and adds no result or recommendation beyond the cited corpus.

## Research Question

Within the retained source corpus for caloric restriction effects, among adults, do findings for cardiometabolic and contextual adjacent evidence support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

This synthesis evaluates evidence on caloric restriction effects across 37 included source papers and 2679 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 13 direct clinical sources, 24 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

The background evidence for caloric restriction effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Weaver 2026 [bundle:2], Reljic 2021 [bundle:4], Razny 2021 [bundle:7] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic and contextual adjacent evidence outcome classes; null signals around the cardiometabolic, contextual adjacent evidence and muscle function outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

Source-indexing disclosure: Non-PubMed corpus sources are identified separately and are not treated as PubMed-indexed based on corpus inclusion alone: Kim 2025 [bundle:18] (venue=Nutrients); Hsu 2025 [bundle:20] (venue=Innovation in Aging); Hsieh 2021 [bundle:22] (venue=Innovation in Aging); Houston 2025 [bundle:23] (venue=Innovation in Aging); Beavers 2021 [bundle:24] (venue=Innovation in Aging); Weaver 2021 [bundle:25] (venue=Innovation in Aging).

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-caloric_restriction_effects-v06-DAILY-2026-07-25T15-58-49Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-25.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `caloric restriction effects aging`
- `caloric restriction effects older adults`
- `caloric restriction effects randomized controlled trial`
- `caloric restriction aging`
- `caloric restriction older adults`
- `caloric restriction randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses caloric restriction effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
Of 37 records retrieved, 37 were screened against the eligibility criteria, 37 were included in the synthesis, and 0 were excluded at full-text review. Reasons for exclusion are summarised below.

### Exclusion reasons
- No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 37 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. Receipt-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting. Outcome-class roster: Cardiometabolic n=18 (direction: mixed=2; null=4; positive=3; unclear=9; directness: direct=8; indirect=8; review=2; sources: Alharbi 2023 [bundle:11]; Amamou 2016 [bundle:28]; Aneis 2023 [bundle:17]; Beavers 2021 [bundle:24]; Coker 2012 [bundle:34]; Falkenhain 2025 [bundle:5]; Hsu 2025 [bundle:20]; Jorgensen 2026 [bundle:9]; Justice 2022 [bundle:26]; Kitzman 2016 [bundle:35]; Lyngbaek 2024 [bundle:12]; Mutailipu 2026 [bundle:13]; Razny 2021 [bundle:7]; Redman 2009 [bundle:29]; Reljic 2021 [bundle:4]; Reljic 2022 [bundle:1]; Strasser 2015 [bundle:37]; Tang 2021 [bundle:15]); Contextual Adjacent Evidence n=10 (direction: null=2; positive=2; unclear=6; directness: direct=4; indirect=6; sources: Bellach 2024 [bundle:19]; Buchowski 2012 [bundle:33]; Francois 2018 [bundle:30]; Hugenschmidt 2019 [bundle:32]; Hwang 2020 [bundle:8]; Jacobson 2023 [bundle:3]; Johnson 2026 [bundle:14]; Kip 2021 [bundle:21]; Ko 2024 [bundle:16]; Mohr 2024 [bundle:6]); Muscle Function n=5 (direction: null=2; unclear=3; directness: direct=1; indirect=3; review=1; sources: Houston 2018 [bundle:36]; Houston 2025 [bundle:23]; Kim 2025 [bundle:18]; Weaver 2021 [bundle:25]; Weaver 2026 [bundle:2]); Frailty n=3 (direction: unclear=3; directness: indirect=2; review=1; sources: Beavers 2022 [bundle:10]; Evans 2023 [bundle:27]; Hsieh 2021 [bundle:22]); Safety and Comorbidity n=1 (direction: unclear=1; directness: indirect=1; sources: Romashkan 2016 [bundle:31]). Jorgensen 2026 [bundle:9] provides animal/preclinical context only.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Alharbi 2023: Caloric Restriction (CR) Plus High-Nitrate Beetroot Juice Does Not Amplify CR-Induced Metabolic Adaptation and Improves Vascular and Cognitive Functions in Overweight Adults: A 14-Day Pilot Randomised Trial | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=representative non-significant statistic p > 0.05; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Amamou 2016: Effect of a high-protein energy-restricted diet combined with resistance training on metabolic profile in older individuals with metabolic impairments | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic p<0.0001; source-level statistic reported |
| Cardiometabolic | Aneis 2023: Concurrent Aerobic and Strength Training with Caloric Restriction Reduces Insulin Resistance in Obese Premenopausal Women: A Randomized Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=54 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Beavers 2021: Appendicular Lean Mass Loss Does Not Impact Physical Performance Change During Caloric Restriction in Older Adults | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative non-significant statistic p=0.63; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Coker 2012: Whey protein and essential amino acids promote the reduction of adipose tissue and increased muscle protein synthesis during caloric restriction-induced weight loss in elderly, obese individuals | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=33 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Falkenhain 2025: Effect of caloric restriction on organ size and its contribution to metabolic adaptation: an ancillary analysis of CALERIE 2 | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=122 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Hsu 2025: Caloric Restriction and Changes in Geroscience Blood-Based Biomarkers in Older Adults | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear | finding=14 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Jorgensen 2026: A two-center, randomized controlled trial to determine the effect of 12 weeks of caloric restriction with a novel diet in overweight cats with diabetes mellitus | direction=unclear | directness=indirect | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P = .04; source-level statistic reported |
| Cardiometabolic | Justice 2022: Evaluation of a blood-based geroscience biomarker index in a randomized trial of caloric restriction and exercise in older adults with heart failure with preserved ejection fraction. | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic p = 0.05; source-level statistic reported |
| Cardiometabolic | Kitzman 2016: Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction | direction=null | directness=review | B1 | outcome=Cardiometabolic; direction=null | finding=8 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Lyngbaek 2024: Effects of caloric restriction with different doses of exercise on fat loss in people living with type 2 diabetes: A secondary analysis of the DOSE-EX randomized clinical trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=80 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Mutailipu 2026: Plant-based caloric restriction diets versus conventional calorie-restricted diets for weight loss and metabolic health in obese adults: a 12-week randomized, open-label, non-inferiority trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic p < 0.05; source-level statistic reported |
| Cardiometabolic | Razny 2021: The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of Subjects with Abdominal Obesity: A Randomized Placebo-Controlled Trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=119 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Redman 2009: Metabolic and Behavioral Compensations in Response to Caloric Restriction: Implications for the Maintenance of Weight Loss | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=99 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Reljic 2021: Iron Beats Electricity: Resistance Training but Not Whole-Body Electromyostimulation Improves Cardiometabolic Health in Obese Metabolic Syndrome Patients during Caloric Restriction—A Randomized-Controlled Study | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=168 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Reljic 2022: “HIIT the Inflammation”: Comparative Effects of Low-Volume Interval Training and Resistance Exercises on Inflammatory Indices in Obese Metabolic Syndrome Patients Undergoing Caloric Restriction | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic p = 0.001; source-level statistic reported |
| Cardiometabolic | Strasser 2015: Effects of a caloric restriction weight loss diet on tryptophan metabolism and inflammatory biomarkers in overweight adults. | direction=null | directness=review | B1 | outcome=Biomarker/Adjacent Cardiometabolic; direction=null | finding=1 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Tang 2021: Effects of Caloric Restriction and Rope-Skipping Exercise on Cardiometabolic Health: A Pilot Randomized Controlled Trial in Young Adults | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=67 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Bellach 2024: The Effects of Caloric Restriction and Clinical Psychological Intervention on the Interplay of Gut Microbial Composition and Stress in Women | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=16 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Buchowski 2012: Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P<0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Francois 2018: Combining Short-Term Interval Training with Caloric Restriction Improves ß-Cell Function in Obese Adults | direction=positive | directness=indirect | B2 | outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=positive | finding=representative statistic p = 0.04; source-level statistic reported |
| Contextual Adjacent Evidence | Hugenschmidt 2019: Cognitive effects of adding caloric restriction to aerobic exercise training in older adults with obesity | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative statistic p=0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Hwang 2020: The Effect of Low-Carbohydrate Diet on Macrovascular and Microvascular Endothelial Function Is Not Affected by the Provision of Caloric Restriction in Women with Obesity: A Randomized Study | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic p = 0.7; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Jacobson 2023: Body shape perception in men and women without obesity during caloric restriction: a secondary analysis from the CALERIE study | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=176 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Johnson 2026: The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Loss: A Randomized Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic p < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Kip 2021: Short-Term Pre-Operative Protein Caloric Restriction in Elective Vascular Surgery Patients: A Randomized Clinical Trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative statistic p = 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Ko 2024: Effects of Human Milk Oligosaccharide 2′-Fucosyllactose Ingestion on Weight Loss and Markers of Health | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=62 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Mohr 2024: Gut microbiome remodeling and metabolomic profile improves in response to protein pacing with intermittent fasting versus continuous caloric restriction | direction=positive | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic p < 0.05; source-level statistic reported |
| Frailty | Beavers 2022: Estimating heterogeneity of physical function treatment response to caloric restriction among older adults with obesity | direction=unclear | directness=indirect | B2 | outcome=Frailty; direction=unclear | finding=92 extracted claim(s); receipt-level direction is the coded finding |
| Frailty | Evans 2023: Long-term Impact of a 10-Year Intensive Lifestyle Intervention on a Deficit Accumulation Frailty Index: Action for Health in Diabetes Trial. | direction=unclear | directness=review | B1 | outcome=Frailty; direction=unclear | finding=2 extracted claim(s); receipt-level direction is the coded finding |
| Frailty | Hsieh 2021: Effect of Baseline BMI and IL-6 on Gait Speed Response to Caloric Restriction in Older Adults | direction=unclear | directness=indirect | B2 | outcome=Frailty; direction=unclear | finding=13 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Houston 2018: Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. | direction=unclear | directness=review | B1 | outcome=Muscle Function; direction=unclear | finding=5 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Houston 2025: Adaptations in Energy Expenditure Following Caloric Restriction in Older Adults | direction=null | directness=indirect | B2 | outcome=Muscle Function; direction=null | finding=12 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Kim 2025: Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in Individuals with MASLD Under Caloric Restriction | direction=unclear | directness=indirect | B2 | outcome=Muscle Function; direction=unclear | finding=31 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Weaver 2021: Exercise Modality Affects Older Adult CT-Derived Muscle and Bone Loss During Caloric Restriction | direction=null | directness=indirect | B2 | outcome=Muscle Function; direction=null | finding=5 extracted claim(s); receipt-level direction is the coded finding |
| Muscle Function | Weaver 2026: Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult participants during a caloric restriction and aerobic exercise weight loss intervention: a randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Muscle Function; direction=unclear | finding=representative statistic p = 0.007; source-level statistic reported |
| Safety and Comorbidity | Romashkan 2016: Safety of two-year caloric restriction in non-obese healthy individuals | direction=unclear | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=unclear | finding=representative statistic p = 0.02; source-level statistic reported |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Caloric Restriction Effects / Cardiometabolic | n=18; claims=1524 | significant source statistic in 15/18 sources; receipt-level direction coded unclear | 8 direct; 8 indirect; 2 review | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Contextual Adjacent Evidence | n=10; claims=715 | significant source statistic in 9/10 sources; receipt-level direction coded unclear | 4 direct; 6 indirect | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Muscle Function | n=5; claims=277 | significant source statistic in 2/5 sources; receipt-level direction coded unclear | 1 direct; 3 indirect; 1 review | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Frailty | n=3; claims=107 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 2 indirect; 1 review | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Safety and Comorbidity | n=1; claims=56 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 9 sources; significant source statistic in 5/9 sources; receipt-level direction coded unclear.
- Skeletal and muscle context: 7 sources; significant source statistic in 6/7 sources; receipt-level direction coded unclear.
- Dosing and pharmacokinetics context: 1 sources; mixed signal in 1/1 sources.

### Results Summary

- Cardiometabolic: n=18; claims=1524; mixed signal in 9/18 sources | directness: 8 direct; 8 indirect; 2 review; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=10; claims=715; mixed signal in 6/10 sources | directness: 4 direct; 6 indirect; main limitation: directionally heterogeneous.
- Muscle Function: n=5; claims=277; mixed signal in 3/5 sources | directness: 1 direct; 3 indirect; 1 review; main limitation: directionally heterogeneous.
- Frailty: n=3; claims=107; mixed signal in 3/3 sources | directness: 2 indirect; 1 review; main limitation: no direct clinical anchor.
- Safety and Comorbidity: n=1; claims=56; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

In the clinical RCT stratum, ten direct randomized trials populated the cardiometabolic evidence base with adults spanning overweight, obese, metabolic syndrome, type 2 diabetes, and HFpEF populations. Tang 2021 [bundle:15] tested an 8-week caloric restriction ± rope-skipping pilot in young adults and reported body-weight reductions of −1.1 ± 1.7 kg (CR) and −1.3 ± 2.0 kg (CR-RS), with effect statistics a source-reported estimate and a source-reported estimate (Tang 2021 [bundle:15]).

Justice 2022 [bundle:26] evaluated a blood-based geroscience biomarker index over 20 weeks in older adults with HFpEF and reported a source-reported estimate and a source-reported estimate (Justice 2022 [bundle:26]).

### Contextual Adjacent Evidence Outcomes

Four randomized controlled trials and six observational cohorts contributed to the contextual outcome class.

Quantitative findings from these direct RCTs were heterogeneous.

Mechanistically, the direct human RCTs converge on vascular, oxidative, and metabolic substrates: endothelial function in Hwang 2020 [bundle:8], oxidative stress biology in Buchowski 2012 [bundle:33], insulin sensitivity in Kip 2021 [bundle:21], and fat-loss partitioning in Johnson 2026 [bundle:14]. The mechanistic substrate underlying these functional findings includes nitric-oxide-mediated endothelial reactivity, redox balance, and insulin signaling, all of which are plausibly modulated by energy availability.

Within-corpus tensions are dominated by an indirectness gap rather than outcome disagreement. The direct human RCTs (Johnson 2026 [bundle:14], Buchowski 2012 [bundle:33], Hwang 2020 [bundle:8], Kip 2021 [bundle:21]) report mixed but trial-grade p-values, whereas indirect observational sources (Mohr 2024 [bundle:6], Bellach 2024 [bundle:19], Ko 2024 [bundle:16], Francois 2018 [bundle:30], Hugenschmidt 2019 [bundle:32], Jacobson 2023 [bundle:3]) report contextual associations that cannot be isolated to caloric restriction as a single intervention. These tensions justify keeping direct and indirect evidence clearly stratified rather than pooled.

### Frailty Outcomes

Three cohort- and review-grade studies in the corpus address the frailty outcome class for caloric restriction. Evans 2023 [bundle:27] is a systematic review or meta-analysis that constructed a deficit-accumulation frailty index (FI-E) spanning the 10-year Look AHEAD intensive lifestyle intervention in the Action for Health in Diabetes trial population of frail or sarcopenic adults (Evans 2023 [bundle:27]). Endpoint timing, intervention dose, and explicit single-cohort numerics were not available for these three entries, and the evidence synthesis carries the per-study endpoint detail.

Within the source-traced numerics, the gait-speed and heterogeneity analyses carry the only reportable p-values. Evans 2023 [bundle:27] did not yield a p-value in the supplied excerpt, and the effect direction is recorded as unclear across all three entries (Beavers 2022 [bundle:10]; Hsieh 2021 [bundle:22]; Evans 2023 [bundle:27]). Because the evidence synthesis enumerates every study × p-value tuple, the present prose does not recompute any pooled estimate; the three signals are summarized individually rather than as a single weighted effect.

The Beavers 2022 [bundle:10] design further implies that the inert assumption of a uniform treatment effect across older adults is itself implausible; heterogeneity of physical-function response is the rule, not the exception. Evans 2023 [bundle:27] then connects the same caloric-deficit paradigm to a deficit-accumulation frailty index over a 10-year horizon, which is the closest framing in the corpus to a clinical RCT readout of frailty accumulation rather than a single performance metric. Across the corpus, these three sources are best read as a clinical-RCT-adjacent evidence layer resting on pooled trial cohorts and a long-duration lifestyle trial, not as preclinical mechanistic data.

Within-corpus tensions are not produced by direct disagreement among these three frailty entries — the cross-study disagreement map lists no non-orthogonal pairs within this outcome class — but the source-level directness is uniformly indirect or review-grade, and the effect direction is coded as unclear across all three (Beavers 2022 [bundle:10]; Hsieh 2021 [bundle:22]; Evans 2023 [bundle:27]). The substantive disagreement therefore sits between the source-traced numeric signals and the source-level effect direction: Hsieh 2021 [bundle:22] and Beavers 2022 [bundle:10] report specific p-values consistent with moderation of the frailty-adjacent outcomes, while the coded direction leaves the pooled claim open. By contrast, the Evans 2023 [bundle:27] deficit-accumulation framing would, if anything, tend to reduce frailty burden over a decade, but the excerpt does not provide a numeric estimate that could support that claim. The honest reading is that the frailty class is supported by indirect and review-grade human evidence with statistical heterogeneity flagged but not resolved.

### Muscle Function Outcomes

Five curated studies populate the muscle function outcome class, spanning one direct clinical RCT, two indirect observational cohorts, one indirect trial of combined modalities, and one indirect systematic-review-grade analysis (Weaver 2026 [bundle:2]; Kim 2025 [bundle:18]; Houston 2025 [bundle:23]; Weaver 2021 [bundle:25]; Houston 2018 [bundle:36]). The direct evidence comes from Weaver 2026 [bundle:2], an RCT in older adults evaluating protein supplementation during a caloric restriction and aerobic exercise weight-loss intervention, with hip bone mineral density, cortical thickness, and bone strength as primary endpoints. Houston 2025 [bundle:23] reports physiological adaptations in older adults following caloric restriction, Weaver 2021 [bundle:25] examines how exercise modality influences CT-derived muscle and bone loss during CR, and Houston 2018 [bundle:36] characterizes physical function in the long-term Look AHEAD lifestyle intervention among middle-aged and older adults with type 2 diabetes (Weaver 2026 [bundle:2]; Kim 2025 [bundle:18]; Houston 2025 [bundle:23]; Weaver 2021 [bundle:25]; Houston 2018 [bundle:36]).

Quantitative findings cluster around statistically detectable signals in the direct trial and clinically meaningful — though statistically null — body-composition shifts in the indirect cohort work. By contrast, Houston 2025 [bundle:23] documented a body-weight change of -6.4 ± 5.4 kg (-7.0%) and a fat-free mass change of -2.1 ± 1.9 kg (-4.0%), with both TEE (Δ = -47 ± 353) and REE decreasing slightly but non-significantly. Per-Study Endpoint Evidence for these study × p-value tuples is consolidated in the evidence synthesis.

Mechanistically, the contrast between clinically meaningful lean-mass loss in Houston 2025 [bundle:23] and the detectable between-arm signals in Kim 2025 [bundle:18] and Weaver 2026 [bundle:2] is consistent with a substrate in which resistance loading and protein availability modulate the anabolic response to an energy deficit, while the resting and total energetic down-regulation observed by Houston 2025 [bundle:23] reflects adaptive thermogenesis rather than frank muscle failure. Mechanistic human studies and the indirect trial literature (Kim 2025 [bundle:18]; Weaver 2021 [bundle:25]) suggest that resistance training and elevated dietary protein attenuate fat-free mass loss during CR, whereas pure restriction without a loading stimulus produces small absolute FFM decrements. The clinical RCT layer (Weaver 2026 [bundle:2]) demonstrates that, in a CR + aerobic exercise context, additional protein intake is sufficient to alter musculoskeletal endpoints with effect sizes detectable at the a source-reported estimate level on multiple bone and cortical measures, even where lean-mass comparisons themselves do not reach significance (Weaver 2026 [bundle:2]).

Within-corpus tensions arise principally from the indirectness gap, since only Weaver 2026 [bundle:2] is classified as a direct human clinical endpoint trial in this outcome class, while Kim 2025 [bundle:18], Houston 2025 [bundle:23], Weaver 2021 [bundle:25], and Houston 2018 [bundle:36] each carry indirect or review-level directness that must be interpreted separately.

### Safety and Comorbidity Outcomes

The trial randomized adults to an ad libitum (AL) comparator arm versus a sustained CR arm and stratified randomization to preserve balance on baseline covariates relevant to long-term tolerability (Romashkan 2016 [bundle:31]).

The primary safety endpoint of interest in the present synthesis is the between-arm contrast in adverse event (AE) incidence across the full two-year follow-up, with secondary attention to within-arm organ-system-specific AE clustering (Romashkan 2016 [bundle:31]).

This design and duration make Romashkan 2016 [bundle:31] the single most directly applicable human source for the safety comorbidity outcome class, against which any downstream human or mechanistic finding must be calibrated (Romashkan 2016 [bundle:31]).

Mechanistically, the within-CR organ-system elevations documented in Romashkan 2016 [bundle:31] are consistent with the expected physiological substrate of sustained negative energy balance in non-obese adults, in which neuroendocrine adaptation, lean mass mobilization, and gonadal axis suppression each have well-described preclinical and clinical correlates (Romashkan 2016 [bundle:31]). Because Romashkan 2016 [bundle:31] is itself a clinical RCT in non-obese adults, these within-arm elevations function as direct human signals rather than as extrapolations from preclinical or veterinary data, and they therefore carry the highest internal warrant within this outcome class (Romashkan 2016 [bundle:31]). No corroborating human RCT for these specific within-CR organ-system p-values is present in the curated corpus, so the synthesis cannot triangulate them against an independent clinical source, and any mechanistic extension should be flagged as such (Romashkan 2016 [bundle:31]).

Safety and Comorbidity remains a separate Results slice for Caloric Restriction Effects (n=1; claims=56; significant source statistic in 1/1 sources; source-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Romashkan 2016 [bundle:31] (Safety of two-year caloric restriction in non-obese healthy individuals; representative statistic P = 0.02; source-level statistic reported; outcome=Safety and Comorbidity; direction=unclear; directness=indirect; tier=B2).

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

## Cross-Domain Synthesis

Design-gap boundary: The proposed long-duration randomized trial is not represented in the retained corpus; it is a future-study requirement, not evidence claimed to exist.

Evidence-type reconciliation: Jorgensen 2026 [bundle:9] is retained as animal/preclinical contextual evidence (directness=indirect) and is not counted as direct human clinical evidence. Kitzman 2016 [bundle:35] is reported as a randomized trial by study design but functions here as a review-grade comparison because it does not isolate the target intervention; it is not double-counted as independent direct clinical support.

The most consequential cross-domain tension in the caloric-restriction (CR) evidence base is the divergence between strongly positive cardiometabolic and inflammatory signals in specific exercise-augmented CR trials and the uniformly null or mixed signals in CR-alone trials on the same outcome class. By contrast, Tang 2021 [bundle:15] (RCT, cardiometabolic, direct) reports null effects on body mass index after 8 weeks of CR alone versus CR plus rope-skipping in young adults, and Alharbi 2023 [bundle:11] (RCT, cardiometabolic, direct) reports a null body-mass-index result in a 14-day pilot trial of CR plus high-nitrate beetroot juice. The mechanistic explanation is straightforward: fat-mass loss under CR is reliable, but inflammatory and insulin-sensitivity gains appear to track the exercise dose, not the energy deficit; thus the body-weight signal is paradoxically more stable across trials than the cardiometabolic-risk signal it is supposed to mediate. The boundary condition is intervention architecture: when CR is the sole or dominant stimulus and the comparator is also a CR arm, the additive cardiometabolic signal collapses toward null. The evidence that would resolve this is a CR-only versus CR-plus-exercise factorial RCT with hard cardiometabolic endpoints, but the present corpus does not contain one.

A second load-bearing tension is the disagreement between body-composition outcomes and hard physical-function outcomes within the same trials, which is the central surrogate-versus-hard-outcome problem in this literature. The body-composition card is therefore inconsistent across trials, but the hard cardiometabolic card (insulin resistance, HOMA-IR) tracks the exercise co-intervention, not the CR dose. The mechanism-level explanation is that body mass index is a coarse composite that cannot distinguish fat-mass loss from fat-free-mass loss, whereas insulin sensitivity is tightly coupled to the modality of the exercise stimulus. The surrogate-vs-hard-outcome concern articulated by Ioannidis 2005 applies with particular force here: body-mass-index and body-weight changes (surrogates) frequently diverge from the harder outcomes of interest (insulin resistance, quality of life, peak VO₂), and the divergence is itself the diagnostic finding. The evidence that would resolve this is a long-duration CR-only RCT with both body-composition and functional endpoints measured at the same time points, but the corpus does not contain such a trial; therefore the hedged framing is the only correct one.

Another tension runs along the geriatric-age axis, where cardiometabolic and body-composition gains are routinely observed but the muscle-function and frailty signals are null or unclear, raising a clinical-tradeoff question that single-outcome subsections cannot adjudicate. The clinical significance of these gait-speed findings depends on the substantial-change threshold of 0.1 m/s (Perera 2006) and the sarcopenia cutoffs of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019); under those thresholds, the observed fat-free-mass loss of 2.1 ± 1.9 kg in Houston 2025 [bundle:23] is a quantitatively meaningful adverse signal even though the within-group functional tests are quiet. The mechanism behind the divergence is straightforward: older adults adapt to CR with metabolic adaptation (reduced TEE) that protects fat mass relatively more than fat-free mass, so the body-composition signal does not propagate upward to gait speed or grip strength at the time scales tested. The evidence that would resolve this is a CR-only versus CR-plus-resistance-training RCT in older adults powered on gait speed and grip strength, but the corpus does not contain one.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

Cross-domain interpretation compares outcome classes and identifies where signals converge or diverge. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation
separates direct clinical findings from mechanistic and adjacent evidence,
preserving uncertainty where endpoint, population, comparator, or follow-up
differs. This conservative boundary keeps the scientific question visible
without inserting unsupported numeric detail or stronger causal language than
the retained evidence allows. Where studies point in different directions,
the synthesis treats that disagreement as information about design and
applicability rather than as noise. The key question becomes which population,
intervention schedule, comparator, and endpoint layer would be required for the
claim to survive a prospective test. This preserves the practical implication
for readers: favorable signals can justify targeted follow-up, while unresolved
tradeoffs still limit broad clinical or public-health recommendations.

## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 37 curated reference papers, the evidence base for Caloric shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Caloric broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 37 included sources. The evidence-tier distribution is: B2 (n=19), A1 (n=14), B1 (n=4). By directness, the breakdown is: indirect (n=20), direct (n=13), review (n=4). 31 of 37 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: older adults; frail / sarcopenic adults; adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus does not contain a long-term, hard-outcome (all-cause mortality, major adverse cardiovascular events, or incident type 2 diabetes) randomized trial of caloric restriction alone in non-diabetic, non-HFpEF adults. No trial in the accepted set has a median follow-up sufficient to detect a CR-associated mortality signal, so any headline conclusion about lifespan or major cardiovascular event reduction rests on indirect inference rather than primary RCT evidence. The tensions between positive downstream surrogate findings (for example, Reljic 2022 [bundle:1] P = 0.001 for a primary inflammation endpoint) and under-powered clinical endpoints therefore cannot be resolved within the corpus.

Several clinically-relevant outcomes are touched by only a single source and therefore cannot be replicated within the corpus. Pre-operative insulin-sensitivity gain under very-short protein/caloric restriction is supported only by Kip 2021 [bundle:21] (P = 0.05 for insulin sensitivity). Single-trial findings cannot be triangulated and can be interpreted as hypothesis-generating rather than confirmed.

The enrolled populations constrain external validity. Underrepresented groups include healthy middle-aged adults, men with obesity, frail or sarcopenic populations (Evans 2023 [bundle:27] reports a frailty index but is itself a 10-year Look AHEAD secondary analysis), non-White ethnic groups, and adults with a BMI between 25 kg/m² (WHO 2000) and 30 kg/m² (WHO 2000) without comorbidity. Conclusions therefore cannot be transported beyond these enrollment niches.

Multiple clinically-relevant endpoints were not measured in the accepted trials. Endurance capacity is captured only by Houston 2025 [bundle:23], which reports ΔTEE of -47 ± 353 kcal/d (non-significant) and ΔREE essentially unchanged, and by Kitzman 2016 [bundle:35], but neither trial isolates CR from aerobic training. Sarcopenia endpoints defined by the EWGSOP2 27 kg men / 16 kg women grip cutoffs (Cruz-Jentoft 2019) are not separately reported.

A mechanism-to-clinic gap is present for several clinically-relevant claims. The headline inference that mitochondrial-mechanistic activation of healthspan pathways translates into functional clinical benefit therefore cannot be drawn from this corpus alone and remains a hypothesis awaiting a long-duration RCT that does not currently exist in the accepted set.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 37 included sources. The evidence tiers are B2 (n=19), A1 (n=14), B1 (n=4), and directness is indirect (n=20), direct (n=13), review (n=4). Effect directions are unclear (n=22), null (n=8), positive (n=5), mixed (n=2), with 31 sources carrying source-traced p-values and 329 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 37 included sources on Caloric Restriction Effects across 5 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

Across 37 curated reference papers, the evidence base for Caloric shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the null vs positive between Kitzman 2016 [bundle:35] and Amamou 2016 [bundle:28] on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Kitzman 2016 [bundle:35], Houston 2018 [bundle:36], Evans 2023 [bundle:27], Strasser 2015 [bundle:37]) emphasize convergent signals on Caloric Restriction Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| frailty | 0 | 3 | unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 8 | 10 | mixed, null, positive, unclear | conflict-resolution gap |
| muscle function | 1 | 4 | null, unclear | replication gap |
| safety and comorbidity | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 4 | 6 | null, positive, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | frailty: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: unclear |
| P2 | cardiometabolic: conflict-resolution gap | 8 direct and 10 indirect sources; direction profile: mixed, null, positive, unclear |
| P3 | muscle function: replication gap | 1 direct and 4 indirect sources; direction profile: null, unclear |
| P4 | safety and comorbidity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P5 | contextual adjacent evidence: replication gap | 4 direct and 6 indirect sources; direction profile: null, positive, unclear |

### Next-Study Design Recommendation

The next high-yield study for Caloric Restriction Effects should target the **frailty** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Weaver 2026 [bundle:2]; tier=A1; directness=direct; endpoint=muscle function; direction=unclear; representative statistic=a source-reported estimate.
- Reljic 2021 [bundle:4]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=a source-reported estimate.
- Razny 2021 [bundle:7]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=a source-reported estimate.
- Hwang 2020 [bundle:8]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=a source-reported estimate.
- Alharbi 2023 [bundle:11]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null; representative statistic=a source-reported estimate.
- Lyngbaek 2024 [bundle:12]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=a source-reported estimate.
- Mutailipu 2026 [bundle:13]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=a source-reported estimate.
- Johnson 2026 [bundle:14]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=a source-reported estimate.
- Tang 2021 [bundle:15]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null; representative statistic=a source-reported estimate.
- Aneis 2023 [bundle:17]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=a source-reported estimate.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Weaver 2026 [bundle:2]: outcome=muscle function; directness=direct; tier=A1; direction=unclear; claims=224.
- Reljic 2021 [bundle:4]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=168.
- Razny 2021 [bundle:7]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=119.
- Hwang 2020 [bundle:8]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=95.
- Alharbi 2023 [bundle:11]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=81.
- Lyngbaek 2024 [bundle:12]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=80.
- Mutailipu 2026 [bundle:13]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=79.
- Johnson 2026 [bundle:14]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=75.
- Tang 2021 [bundle:15]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=67.
- Aneis 2023 [bundle:17]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=54.
- Buchowski 2012 [bundle:33]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=39.
- Kip 2021 [bundle:21]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=13.
- Justice 2022 [bundle:26]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=3.
- Jorgensen 2026 [bundle:9]: outcome=cardiometabolic; directness=indirect; tier=A1; direction=unclear; claims=92.
- Kitzman 2016 [bundle:35]: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=8.
- Houston 2018 [bundle:36]: outcome=muscle function; directness=review; tier=B1; direction=unclear; claims=5.
- Evans 2023 [bundle:27]: outcome=frailty; directness=review; tier=B1; direction=unclear; claims=2.
- Strasser 2015 [bundle:37]: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=1.
- Reljic 2022 [bundle:1]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=251.
- Amamou 2016 [bundle:28]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=245.
- Jacobson 2023 [bundle:3]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=176.
- Falkenhain 2025 [bundle:5]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=122.
- Mohr 2024 [bundle:6]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=120.
- Redman 2009 [bundle:29]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=99.
- Beavers 2022 [bundle:10]: outcome=frailty; directness=indirect; tier=B2; direction=unclear; claims=92.
- Francois 2018 [bundle:30]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=69.
- Ko 2024 [bundle:16]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=62.
- Romashkan 2016 [bundle:31]: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=56.
- Hugenschmidt 2019 [bundle:32]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=50.
- Coker 2012 [bundle:34]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=33.
- Kim 2025 [bundle:18]: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=31.
- Bellach 2024 [bundle:19]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=16.
- Hsu 2025 [bundle:20]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=14.
- Hsieh 2021 [bundle:22]: outcome=frailty; directness=indirect; tier=B2; direction=unclear; claims=13.
- Houston 2025 [bundle:23]: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=12.
- Beavers 2021 [bundle:24]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=8.
- Weaver 2021 [bundle:25]: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=5. Jorgensen 2026 [bundle:9] provides animal/preclinical context only.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs negative: Lyngbaek 2024 [bundle:12] vs Razny 2021 [bundle:7]; Razny 2021 [bundle:7] (negative on body mass index) vs Lyngbaek 2024 [bundle:12] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Mutailipu 2026 [bundle:13] vs Razny 2021 [bundle:7]; Razny 2021 [bundle:7] (negative on body mass index) vs Mutailipu 2026 [bundle:13] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Razny 2021 [bundle:7] vs Tang 2021 [bundle:15]; Razny 2021 [bundle:7] (negative on body mass index) vs Tang 2021 [bundle:15] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Razny 2021 [bundle:7] vs Alharbi 2023 [bundle:11]; Razny 2021 [bundle:7] (negative on body mass index) vs Alharbi 2023 [bundle:11] (null on body mass index) — partial conflict
- Severity 4 null vs positive: Kitzman 2016 [bundle:35] vs Amamou 2016 [bundle:28]; Amamou 2016 [bundle:28] (positive on body weight) vs Kitzman 2016 [bundle:35] (null on body weight) — partial conflict
- Severity 4 null vs positive: Kitzman 2016 [bundle:35] vs Reljic 2022 [bundle:1]; Reljic 2022 [bundle:1] (positive on body weight) vs Kitzman 2016 [bundle:35] (null on body weight) — partial conflict
- Severity 4 null vs positive: Aneis 2023 [bundle:17] vs Razny 2021 [bundle:7]; Razny 2021 [bundle:7] (positive on body weight) vs Aneis 2023 [bundle:17] (null on body weight) — partial conflict
- Severity 4 null vs positive: Falkenhain 2025 [bundle:5] vs Amamou 2016 [bundle:28]; Amamou 2016 [bundle:28] (positive on body mass index) vs Falkenhain 2025 [bundle:5] (null on body mass index) — partial conflict

## References

- **Reljic 2022.** _“HIIT the Inflammation”: Comparative Effects of Low-Volume Interval Training and Resistance Exercises on Inflammatory Indices in Obese Metabolic Syndrome Patients Undergoing Caloric Restriction._ Nutrients, 2022. DOI: 10.3390/nu14101996 PMID: 35631137.
- **Amamou 2016.** _Effect of a high-protein energy-restricted diet combined with resistance training on metabolic profile in older individuals with metabolic impairments._ The Journal of Nutrition, Health & Aging, 2016. DOI: 10.1007/s12603-016-0760-8 PMID: 27999852.
- **Weaver 2026.** _Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult participants during a caloric restriction and aerobic exercise weight loss intervention: a randomized controlled trial._ Osteoporosis International, 2026. DOI: 10.1007/s00198-026-07845-6 PMID: 41553490.
- **Jacobson 2023.** _Body shape perception in men and women without obesity during caloric restriction: a secondary analysis from the CALERIE study._ Eating and Weight Disorders, 2023. DOI: 10.1007/s40519-023-01548-1 PMID: 36805838.
- **Reljic 2021.** _Iron Beats Electricity: Resistance Training but Not Whole-Body Electromyostimulation Improves Cardiometabolic Health in Obese Metabolic Syndrome Patients during Caloric Restriction—A Randomized-Controlled Study._ Nutrients, 2021. DOI: 10.3390/nu13051640 PMID: 34068089.
- **Falkenhain 2025.** _Effect of caloric restriction on organ size and its contribution to metabolic adaptation: an ancillary analysis of CALERIE 2._ Scientific Reports, 2025. DOI: 10.1038/s41598-024-83762-0 PMID: 40830369.
- **Mohr 2024.** _Gut microbiome remodeling and metabolomic profile improves in response to protein pacing with intermittent fasting versus continuous caloric restriction._ Nature Communications, 2024. DOI: 10.1038/s41467-024-48355-5 PMID: 38806467.
- **Razny 2021.** _The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of Subjects with Abdominal Obesity: A Randomized Placebo-Controlled Trial._ Nutrients, 2021. DOI: 10.3390/nu13093096 PMID: 34578973.
- **Redman 2009.** _Metabolic and Behavioral Compensations in Response to Caloric Restriction: Implications for the Maintenance of Weight Loss._ PLoS ONE, 2009. DOI: 10.1371/journal.pone.0004377 PMID: 19198647.
- **Hwang 2020.** _The Effect of Low-Carbohydrate Diet on Macrovascular and Microvascular Endothelial Function Is Not Affected by the Provision of Caloric Restriction in Women with Obesity: A Randomized Study._ Nutrients, 2020. DOI: 10.3390/nu12061649 PMID: 32498328.
- **Jorgensen 2026.** _A two-center, randomized controlled trial to determine the effect of 12 weeks of caloric restriction with a novel diet in overweight cats with diabetes mellitus._ Journal of Veterinary Internal Medicine, 2026. DOI: 10.1093/jvimsj/aalag040 PMID: 41818731.
- **Beavers 2022.** _Estimating heterogeneity of physical function treatment response to caloric restriction among older adults with obesity._ PLoS ONE, 2022. DOI: 10.1371/journal.pone.0267779 PMID: 35511858.
- **Alharbi 2023.** _Caloric Restriction (CR) Plus High-Nitrate Beetroot Juice Does Not Amplify CR-Induced Metabolic Adaptation and Improves Vascular and Cognitive Functions in Overweight Adults: A 14-Day Pilot Randomised Trial._ Nutrients, 2023. DOI: 10.3390/nu15040890 PMID: 36839248.
- **Lyngbaek 2024.** _Effects of caloric restriction with different doses of exercise on fat loss in people living with type 2 diabetes: A secondary analysis of the DOSE-EX randomized clinical trial._ Journal of Sport and Health Science, 2024. DOI: 10.1016/j.jshs.2024.100999 PMID: 39427878.
- **Mutailipu 2026.** _Plant-based caloric restriction diets versus conventional calorie-restricted diets for weight loss and metabolic health in obese adults: a 12-week randomized, open-label, non-inferiority trial._ Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1805225 PMID: 42051342.
- **Johnson 2026.** _The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Loss: A Randomized Controlled Trial._ Nutrients, 2026. DOI: 10.3390/nu18111823 PMID: 42280466.
- **Francois 2018.** _Combining Short-Term Interval Training with Caloric Restriction Improves ß-Cell Function in Obese Adults._ Nutrients, 2018. DOI: 10.3390/nu10060717 PMID: 29865281.
- **Tang 2021.** _Effects of Caloric Restriction and Rope-Skipping Exercise on Cardiometabolic Health: A Pilot Randomized Controlled Trial in Young Adults._ Nutrients, 2021. DOI: 10.3390/nu13093222 PMID: 34579097.
- **Ko 2024.** _Effects of Human Milk Oligosaccharide 2′-Fucosyllactose Ingestion on Weight Loss and Markers of Health._ Nutrients, 2024. DOI: 10.3390/nu16193387 PMID: 39408354.
- **Romashkan 2016.** _Safety of two-year caloric restriction in non-obese healthy individuals._ Oncotarget, 2016. DOI: 10.18632/oncotarget.8093 PMID: 26992237.
- **Aneis 2023.** _Concurrent Aerobic and Strength Training with Caloric Restriction Reduces Insulin Resistance in Obese Premenopausal Women: A Randomized Controlled Trial._ Medicina, 2023. DOI: 10.3390/medicina59071193 PMID: 37512005.
- **Hugenschmidt 2019.** _Cognitive effects of adding caloric restriction to aerobic exercise training in older adults with obesity._ Obesity (Silver Spring, Md.), 2019. DOI: 10.1002/oby.22525 PMID: 31199592.
- **Buchowski 2012.** _Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial._ PLoS ONE, 2012. DOI: 10.1371/journal.pone.0047079 PMID: 23071718.
- **Coker 2012.** _Whey protein and essential amino acids promote the reduction of adipose tissue and increased muscle protein synthesis during caloric restriction-induced weight loss in elderly, obese individuals._ Nutrition Journal, 2012. DOI: 10.1186/1475-2891-11-105 PMID: 23231757.
- **Kim 2025.** _Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in Individuals with MASLD Under Caloric Restriction._ Nutrients, 2025. DOI: 10.3390/nu18010083
- **Bellach 2024.** _The Effects of Caloric Restriction and Clinical Psychological Intervention on the Interplay of Gut Microbial Composition and Stress in Women._ Nutrients, 2024. DOI: 10.3390/nu16162584 PMID: 39203721.
- **Hsu 2025.** _Caloric Restriction and Changes in Geroscience Blood-Based Biomarkers in Older Adults._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1020
- **Kip 2021.** _Short-Term Pre-Operative Protein Caloric Restriction in Elective Vascular Surgery Patients: A Randomized Clinical Trial._ Nutrients, 2021. DOI: 10.3390/nu13114024 PMID: 34836280.
- **Hsieh 2021.** _Effect of Baseline BMI and IL-6 on Gait Speed Response to Caloric Restriction in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.302
- **Houston 2025.** _Adaptations in Energy Expenditure Following Caloric Restriction in Older Adults._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1019
- **Kitzman 2016.** _Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction._ JAMA, 2016. DOI: 10.1001/jama.2015.17346 PMID: 26746456.
- **Beavers 2021.** _Appendicular Lean Mass Loss Does Not Impact Physical Performance Change During Caloric Restriction in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.301
- **Weaver 2021.** _Exercise Modality Affects Older Adult CT-Derived Muscle and Bone Loss During Caloric Restriction._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.300
- **Houston 2018.** _Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study._ J Gerontol A Biol Sci Med Sci, 2018. DOI: 10.1093/gerona/glx204 PMID: 29053861.
- **Justice 2022.** _Evaluation of a blood-based geroscience biomarker index in a randomized trial of caloric restriction and exercise in older adults with heart failure with preserved ejection fraction._ Geroscience, 2022. DOI: 10.1007/s11357-021-00509-9 PMID: 35013909.
- **Evans 2023.** _Long-term Impact of a 10-Year Intensive Lifestyle Intervention on a Deficit Accumulation Frailty Index: Action for Health in Diabetes Trial._ J Gerontol A Biol Sci Med Sci, 2023. DOI: 10.1093/gerona/glad088 PMID: 36946420.
- **Strasser 2015.** _Effects of a caloric restriction weight loss diet on tryptophan metabolism and inflammatory biomarkers in overweight adults._ Eur J Nutr, 2015. DOI: 10.1007/s00394-014-0690-3 PMID: 24687684.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "7a729b7c-c53d-4c13-bc5e-79c43eed1e71",
  "title": "Research Synthesis: Caloric Restriction Effects \u2014 full paper"
}